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   ABSTRACT 
  Objectives      Methotrexate (MTX) is the mainstay 
treatment for juvenile idiopathic arthritis (JIA), however 
approximately 30% of children will fail to respond to the 
drug. Identiﬁ  cation of genetic predictors of response to 
MTX would be invaluable in developing optimal treatment 
strategies for JIA. Using a candidate gene approach, 
single nucleotide polymorphisms (SNPs) within genes 
in the metabolic pathway of MTX, were investigated for 
association with response to treatment in JIA cases.   
  Methods      Tagging SNPs were selected across 13 
MTX metabolic pathway genes and were genotyped 
using Sequenom genotyping technology in subjects 
recruited from the Sparks Childhood Arthritis Response to 
Medication Study. Response to MTX was deﬁ  ned using 
the American College of Rheumatology (ACR) paediatric 
response criteria and SNP genotype frequencies were 
compared between the worst and best responders (ACR-
Ped70) to MTX. An independent cohort of US JIA cases 
was available for validation of initial ﬁ  ndings.   
  Results      One SNP within the inosine triphosphate 
pyrophosphatase gene (  ITPA  ) and two SNPs within 
5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase gene (  ATIC  ) were signiﬁ  cantly associated 
with a poor response to MTX. One of the   ATIC   SNPs 
showed a trend towards association with MTX response 
in an independent cohort of US JIA cases. Meta-analysis 
of the two studies strengthened this association 
(combined p value=0.002).   
  Conclusions      This study presents association of a SNP 
in the   ATIC   gene with response to MTX in JIA. There is 
now growing evidence to support a role of the   ATIC   gene 
with response to MTX treatment. These results could 
contribute towards a better understanding of and ability 
to predict MTX response in JIA.           
  INTRODUCTION 
  Juvenile idiopathic arthritis (JIA) is the most com-
mon arthritic disease of childhood, affecting 1 in 
1000 children and is an important cause of dis-
ability.    1    Methotrexate (MTX) is the mainstay 
treatment in JIA and among those children who 
respond to MTX (65% to 70%) some can enter 
prolonged remission and have a much improved 
quality of life.    2        3    Unfortunately, for children who 
fail to respond, the delay in identifying the opti-
mal treatment, such as biological treatment, at an 
early stage of disease can lead to long-term joint 
damage. Treatment response is thought to be a 
complex trait caused by a combination of genetic 
and environmental factors.    4    Identiﬁ  cation of clini-
cal or genetic predictors of response to MTX would 
be valuable in developing optimal, individualised 
treatment strategies. Candidate gene studies inves-
tigating genes encoding enzymes involved in a 
drug’s metabolism or coding for the drug targets 
have been successful in identifying genetic factors 
for treatment response.    5    
  The precise mode of action of MTX is unknown,    6    
but there is some understanding of its metabolic 
pathway (  ﬁ  gure  1  ) which gives rise to a num-
ber of candidate genes. MTX is a folate analogue 
and enters the cell via the reduced folate carrier 
(SLC19A1). Once inside the cell it is polyglutamated, 
catalysed by the enzyme folylpolyglutamate syn-
thetase (FPGS) (this can be reversed via the enzyme 
γ-glutamyl hydrolase (GGH)). MTX polyglutamates 
act on several key enzymes including thymidylate 
synthase (TYMS) that affects pyrimidine synthesis, 
dihydrofolate reductase (DHFR) that affects folate 
synthesis and 5-aminoimidazole-4-carboxamide 
ribonucleotide transformylase (ATIC) that affects 
purine synthesis. The pathway most potently 
inhibited by MTX polyglutamates is the conver-
sion of 5-  aminoimidazole-4-  carboxamide ribonu-
cleotide (AICAR) to formyl-AICAR by the enzyme 
ATIC. The latter two pathways are thought to lead 
to accumulation of adenosine, which is a potent 
anti-inﬂ  ammatory mediator. Members of the ATP-
binding cassette (ABC) family of transporters play 
a role in the efﬂ  ux of MTX from the cell. There 
are many studies that have reported association 
of single nucleotide polymorphisms (SNPs) within 
genes in the MTX metabolic pathway and toxicity 
or response to MTX in diseases such as rheuma-
toid arthritis (RA) and psoriasis. However, many of 
these show inconsistent ﬁ  ndings and lack of vali-
dation in independent datasets. There have been 
very few studies in JIA.    7        8    Therefore the aim of this 
study was to perform a thorough investigation of 
SNPs across 13 MTX pathway genes on the efﬁ  -
cacy of MTX in patients with JIA.     
  MATERIALS  AND  METHODS 
  Patients 
  This work was performed as part of the Sparks 
CHARMS (for ‘CHildhood Arthritis Response to 
Medication Study’), which recruits children who 
fulﬁ   l International League of Associations for 
Rheumatology (ILAR) criteria for JIA   9    of all subtypes 
and who are about to start new disease-modifying 
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the deﬁ  nition of improvement (DOI) for JIA these six items of 
data are each considered at the start of the therapeutic inter-
vention and after a deﬁ  ned period of time, typically 6 months. 
The DOI to achieve American College of Rheumatology (ACR)-
Ped30 for JIA is when there is at least 30% improvement from 
baseline in three of any the six variables, with no more than 
one of the remaining variables worsening by >30%. ACR-Ped50 
and ACR-Ped70 for JIA require improvements of 50% or 70% in 
at least three of the variables, respectively, again with no more 
than one of the remaining variables worsening by >30%.    10    For 
this study we deﬁ  ned non-responders (NR) as failure to reach 
even the 30% response improvement (  table 1  ).   
  Venous blood samples were taken when the child required 
blood sampling for routine clinical care. This study uses the ﬁ  rst 
197 children in CHARMS on whom full core set variable clinical 
data and DNA samples were available. 
  For validation of the initial ﬁ  ndings, DNA from a replication 
cohort of 210 children with polyarticular or oligoarticular JIA 
from Cincinnati Children’s Hospital Medical Centre, who had 
medication for active arthritis. The study has full ethical com-
mittee approval (Institute of Child Health/Great Ormond Street 
NHS Trust Ethics Committee) and was fully compliant with 
the Declaration of Helsinki. Subjects were recruited with fully 
informed parental consent and child assent where appropriate. 
Demographic and clinical data were collected at baseline (up to 
4 weeks before commencing MTX) and after 6 months of MTX. 
Weekly MTX was given by either oral or subcutaneous route 
at 10–15 mg/m  2  . Data allowing assessment of clinical response 
to the drug was collected using the validated core set variables 
and the Deﬁ  nition of Improvement for JIA.    10    The variables in 
the core set are: doctor’s global assessment of disease activ-
ity (scored on a visual analogue scale of 0–10 with 0=inactive 
and 10=most severe), parent/patient global assessment of over-
all well-being (scored on a visual analogue scale of 0–10 with 
0=very well and 10=very bad), functional ability (measured by 
the Childhood Health Assessment Questionnaire),    11    number of 
joints with active arthritis, number of joints with restricted range 
of movement and the erythrocyte sedimentation rate (mm/h). In 
 Figure  1        Schematic diagram of the key enzymes and pathways involved in the metabolism of methotrexate (MTX). Genes investigated in this study 
are highlighted in blue. Modiﬁ  ed with permission from PharmGKB. (  http://www.pharmgkb.org/do/serve?objId=PA2039&objCls=Pathway ).  28      
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allele and genotype frequencies between the best responders 
(ACR-Ped70 0r 70% improvement in joint count) and the worst 
responders (NR).   
  SNP  selection 
  A total of 13 genes known to be in the MTX pathway were 
selected for SNP genotyping (  ﬁ  gure  1  ). These were   ABCG2  , 
  ADORA2A  ,  AMPD1  ,  ATIC  ,  DHFR  ,  FPGS  ,  GGH  ,  ITPA  ,  MTHFD1  , 
  MTHFR  ,   SHMT1  ,   SLC19A1   (  RFC  ) and   TYMS  . Pairwise tagging 
SNPs for each gene were selected using HapMap release 22 
(  http://www.hapmap.org  ) and the tagger function in Haploview 
version 4.1    12    (  http://www.broadinstitute.org/haploview/haplo-
view  ), using an r  2   cut-off ≥0.8 and minor allele frequency (MAF) 
≥0.05 within 10 kb upstream and downstream of each gene. In 
all, 127 SNPs were selected for genotyping.   
  Genotyping 
  SNP genotyping was performed using the Sequenom iPlex 
MassARRAY platform according to the manufacturers instruc-
tions (Sequenom, San Diego, California, USA.   http://www.
sequenom.com/  ). Only samples and SNPs exceeding a 90% suc-
cess rate were used in the analysis. 
  For the US replication cohort SNPs were genotyped using the 
Affymetrix Genome-Wide Human SNP Array 6.0.   
  Statistical  analysis 
  Genotype frequencies were compared between non-responders 
and the best responders to MTX (ACR-Ped70 or 70% improve-
ment in joint count) using the trend test and allelic ORs with 
95% CIs were calculated using PLINK    13    (  http://pngu.mgh.har-
vard.edu/~purcell/plink/index.shtml  ). Meta-analysis was per-
formed using STATA (Stata, College Station, Texas, USA). A test 
for heterogeneity between cohorts was carried out using the 
Breslow–Day test and a meta-analysis of the two cohorts was 
performed using the Cochran–Mantel–Haenszel test.     
  RESULTS 
  We present results from the ﬁ  rst 197 children in CHARMS on 
whom full core set variable clinical data and DNA samples were 
available, with replication of genetic ﬁ  ndings in a US cohort (210 
children). The numbers for each response deﬁ  nition for the two 
cohorts are summarised in   table 1   and the demographic data 
summarised in   table 2  . Note that all children who reach ACR-
Ped70 automatically also reach ACR-Ped30 and ACR-Ped50, 
while those who achieve ACR-Ped50 also achieve ACR-Ped30. 
Subtype distribution and disease activity was as expected 
for use of MTX in JIA and in line with previous studies.    3    As 
also been treated with MTX and analysed pre treatment and 
at 6 months, were available. SNPs were genotyped using the 
Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, 
Santa Clara, California, USA).   The study had full ethical com-
mittee approval (Cincinnati Children’s Hospital Medical Center 
Institutional Review Board (CCHMC IRB)) and was fully com-
pliant with the Declaration of Helsinki. In this patient cohort 
improvement of arthritis was deﬁ  ned using active joint count 
alone. Levels of improvement at 30%, 50% and 70% were 
deﬁ   ned, and non-responders (NR) were those who did not 
reach a 30% response improvement (  table 1  ). For the analy-
sis we compared the most extreme phenotypes, so compared 
  Table  1         Response criteria and numbers for the UK and US cohorts of 
patients with juvenile idiopathic arthritis (JIA)   
 Cohort    UK cohort (n=197)    US cohort (n=210)* 
ACR-Ped30 141 (71.5%)†  
30% improvement in joint count   131 (63%)
ACR-Ped50 119 (60.4%)  
50% improvement in joint count   107 (52%)
ACR-Ped70 84 (43%)  
70% improvement in joint count   67 (32%)
Non-responders 56 (28%) 76 (37%)
      *Data was missing for three individuals for whom response could not be assessed. 
  †Note that all children who reach ACR-Ped70 automatically also reach ACR-Ped30 and 
ACR-Ped50, while those who achieve ACR-Ped50 also achieve ACR-Ped30. 
  ACR, American College of Rheumatology.     
  Table  2         Demographics of UK and US cohorts of patients with juvenile 
idiopathic arthritis (JIA)   
 Cohort   UK  cohort   US  cohort 
Number of cases 197 210
JIA Subtype at time of starting MTX (%):
 Oligoarticular  persistent 9.1 8.6
 Oligoarticular  extended 26.4 20.9
 Polyarticular  RF− 37.6 67.6
 Polyarticular  RF+ 5.6 1.9
  Enthesitis related arthritis 6.0 0
 Psoriatic 2.5 0.95
 Systemic 10.7 0
 Unclassiﬁ   ed 2.0 0
  Female (%) 132 (67%) 164 (78%)
    Median and range of disease duration at starting 
MTX (decimal years)
1.00, 11.53 1.08, 15.8
    Median and range of age at starting MTX (decimal 
years)
7.93, 14.97 7.25, 18.91
  Median and range of active joints at start of MTX 6, 34 8, 61
  Median and range of restricted joints at start of MTX 4, 41 4, 44
   MTX,  methotrexate;  RF,  rheumatoid  factor.   
  Table  3         SNPs signiﬁ  cantly associated with response to MTX (p<0.05) in UK CHARMS dataset   
 SNP   Gene   Chromosome   Position   Minor  allele   Major  allele   MAF  NR   MAF  ACR-Ped70    OR (95% CI)   p  Trend 
rs12995526 ATIC 2 215906216 C T 0.57 0.42 1.79 (1.07 to 3.00) 0.02
rs4673990 ATIC 2 215914298 G A 0.48 0.35 1.69 (1.01 to 2.83) 0.04
rs2295553 ITPA 20 3132134 C T 0.53 0.39 1.73 (1.03 to 2.89) 0.05
      ACR, American College of Rheumatology; CHARMS, CHildhood Arthritis Response to Medication Study; MAF, minor allele frequency; NR, non-responder; SNP, single nucleotide polymorphism.     
  Table  4         ATIC SNPs investigated for association with response to MTX in the US Cincinnati dataset     
 SNP   Gene   Chromosome   Position   Minor  allele   Major  allele   MAF  NR   MAF  70%    OR (95% CI)   p  Trend 
rs13005416* ATIC 2 216196045 C A 0.51 0.39 1.62 (1.01 to 2.59) 0.07
rs4673990 ATIC 2 215914298 C T 0.45 0.52 0.76 (0.48 to 1.21) 0.29
   * r  2  =1 with rs12995526. 
  MAF, minor allele frequency; MTX, methotrexate; NR, non-responder; SNP, single nucleotide polymorphism.     
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of the   ATIC   SNP with a poor response to MTX, with a combined 
p value of 0.002, a pooled OR 1.7, 95% CI 1.2 to 2.4. There was 
no signiﬁ  cant evidence for heterogeneity between the studies 
(p=0.77) (  ﬁ  gure 2  ).     
  DISCUSSION 
  The ultimate aim of therapies for the treatment of JIA is to attain 
complete control of the disease, to prevent joint damage, maxi-
mise a child’s physical and psychological well-being and prevent 
any long-term consequences related to the disease or treatment.    1    
MTX has transformed the prognosis of children with active JIA,    6    
however for the third of children who fail to respond to MTX 
the delay in ﬁ  nding the appropriate treatment may be crucial in 
terms of their disease outcome, with the risk of joint damage 
and potential permanent disability. Consequently, identifying 
predictors of MTX response would be a major advancement in 
the treatment of JIA. 
  Candidate gene studies have been previously successful in 
identifying genes with signiﬁ  cant contributions to drug response; 
genes encoding enzymes involved in the drug metabolism or 
coding for the drug targets have been shown to be important.    5    
For example, the association of SNPs within   VKORC1      15    and 
  CYP2C9      16       –       18    with warfarin dose variability. The latter gene 
encodes the main metabolising enzyme for the anticoagulant 
and the former is the warfarin drug target. These ﬁ  ndings have 
since been validated in genome-wide association studies.    19        20    
Thus it could be hypothesised that investigating SNPs within 
genes in the MTX metabolic pathway may help to identify 
genetic factors for MTX response. Only two published studies to 
date have investigated MTX pathway genes in response to MTX 
in JIA.    7        8    Both these studies investigated individual polymor-
phisms within MTX pathway genes that have been previously 
expected, there was a higher prevalence of women in both 
cohorts. Disease duration has been recently reported as linked 
with MTX response    14   : the median time of disease duration prior 
to starting MTX in these two cohorts was around 1 year.   
  Results for all SNPs are shown in supplementary   table 1  . Of 
the 127 SNPs genotyped in the CHARMS UK cohort, 10 SNPs 
failed SNP QC, leaving 117 SNPs for analysis. There was an 
average coverage of all genes after QC of >89%. Of the 117 
SNPs analysed, 3 SNPs were found to be signiﬁ  cantly associated 
with MTX response (p<0.05). Two of the SNPs (rs12995526 and 
rs4673990) lie within the   ATIC   gene and are associated with an 
increased risk of having a poor response to MTX (OR 1.79, 95% 
CI 1.07 to 3.0 and OR 1.69, 95% CI 1.01 to 2.83, respectively) 
(  table 3  ). The third associated SNP, rs2295553, lies within the 
inosine triphosphate pyrophosphatase gene (  ITPA  ) and also con-
ferred an increased risk of having a poor response to MTX (OR 
1.73, 95% CI 1.03 to 2.89) (  table 3  ).   
  Signiﬁ  cantly associated SNPs were assessed in a validation 
cohort (US cases) where genotype data was available for two 
of the three most signiﬁ  cantly associated SNPs, the   ITPA   SNP, 
rs2295553, was not genotyped on the Affymetrix array and 
there were no proxies (r  2  >0.8) for this SNP. 
  Of the two   ATIC   SNPs, one SNP had been directly genotyped 
and showed no evidence for association with MTX response 
(OR 0.76, 95% CI 0.48 to 1.21), the other SNP, rs13005416, is 
a complete proxy for rs12995526 and showed a trend towards 
association with MTX response (OR 1.62, 95% CI 1.01 to 2.59) 
(  table 4  ). 
  The sample sizes of the discovery cohort and the validation 
cohort are relatively small and so the results for rs1295526 (and 
its proxy rs13005416 in the US cohort) were combined in a 
meta-analysis. This strengthened the evidence of an association 
 Figure  2        Meta-analysis of rs12995526 and its proxy, rs13005416 in the UK CHARMS (for ‘CHildhood Response to Medication Study’) and US 
Cincinnati datasets. Forest plot displaying ORs and 95% CIs for each of the two studies (UK and US) and the weighting for each study according to 
sample size. The combined OR from the two studies (1.7) is displayed as a diamond with the peaks denoting the upper and lower limits of the CIs 
(1.2 to 2.4). The combined p value for association with methotrexate (MTX) response was 0.002. The Breslow–Day test was performed to test for 
heterogeneity between the two studies, and showed no evidence for heterogeneity (p=0.77).       
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is a threonine to serine substitution at position 116 of the   ATIC   
gene. There have been three studies to date investigating asso-
ciation of this SNP with MTX response in RA. In two studies 
carriers of the minor GG genotype were associated with good 
response to MTX,    22        23    however in the third study the major CC 
genotype carriers were associated with good clinical response to 
MTX.    24    It has been proposed that these conﬂ  icting results may 
be due to differences in the population (early onset versus estab-
lished RA) and in study design (longitudinal data versus cross 
sectional data). This SNP has also been investigated for associa-
tion with MTX response in JIA cases, however, no association 
was found.    8    In this study we did not directly genotype this SNP, 
but genotyped rs4672768 which has an r  2  =1 with rs2372536. 
There was no signiﬁ  cant evidence for association of this SNP 
with MTX response. Another SNP, rs4535042, in the 5’ untrans-
lated region (UTR) of the ATIC gene was also associated with 
a poor response to MTX in a Serbian RA cohort, however, this 
SNP has not been genotyped in this study and is not on HapMap 
so LD with our most associated SNP cannot be determined.    25    In 
a recent investigation of the MTX pathway genes in a cohort of 
patients with RA the intronic ATIC SNP, rs12995526, which we 
found associated with poor response to MTX in JIA was also 
associated with poor response to MTX in RA with similar effect 
sizes (p=0.04 OR 1.51 95% CI 1.0 to 2.28).    26    
  Taking all of this data into consideration, there is growing 
evidence to support the role of the   ATIC   gene in the response 
to MTX treatment. ATIC is the enzyme that is most potently 
inhibited by MTX polyglutamates, it is involved in the conver-
sion of AICAR to formyl-AICAR. AICAR and its metabolites 
inhibit two enzymes important in adenosine metabolism caus-
ing intracellular accumulation of adenosine (  ﬁ  gure 1  ). Adenosine 
is a potent anti-inﬂ  ammatory mediator and it is thought that 
it is this pathway which is important in the mode of action of 
MTX.    27    It could be hypothesised that defects in ATIC could lead 
to decreased enzyme activity and affect AICAR accumulation 
and adenosine release. 
  In conclusion, we have found preliminary evidence that 
a genetic variant in   ATIC  , a key MTX pathway gene, is 
associated with MTX response in JIA. The C allele of SNP, 
rs12995526 is associated with poor response to MTX, and this 
ﬁ  nding is conﬁ  rmed in an independent cohort of JIA cases. 
Additional validation is necessary and further investigations 
will be required to identify the causal variant. Prospective 
studies will be required to determine the predictive value of 
these genetic risk factors.       
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investigated for response to treatment in other diseases that 
are treated with MTX, such as RA and psoriasis. In this study, 
rather than just analyse the previously reported SNPs, we took 
the approach of screening the whole gene using a tagging SNP 
approach. This was a more thorough approach and enabled us 
to have >89% coverage of the genes investigated. 
  Of the two previous studies investigating response to MTX 
in patients with JIA, the ﬁ  rst looked at the two polymorphisms 
(C677T and A1298C) in the   MTHFR   gene, which is probably 
the best studied gene in the MTX metabolic pathway. The 
SNPs have previously shown evidence of association with MTX 
response and adverse drug reactions in cancer and adult RA.    21    
This study found the 677T allele to be associated with greater 
toxicity and the 1298C allele with better efﬁ  cacy.    7    In our study 
we have not investigated toxicity but there was a trend towards 
the 677T allele being associated with a good response to MTX. 
We had not directly genotyped the A1298C SNP but the SNP, 
rs4846049, which had an r  2  =0.93 with the A1298C SNP, showed 
no evidence for association with response to MTX. The second 
study in JIA tested SNPs within   AMPD1  ,   ATIC  ,   ITPA  ,   MTHFD1   
and   MTHFR   for association with response to MTX in JIA. The 
  MTHFR   1298A-677C haplotype analysis showed carriage of 
two copies of the 1298A-677C haplotype was associated with 
good response to MTX.    8    
  Our study found signiﬁ  cant evidence for association of three 
SNPs, two within the   ATIC   gene and one within   ITPA  , with 
response to MTX. Multiple testing is an issue and if we per-
formed a Bonferroni correction for the number of SNPs tested 
none would remain signiﬁ  cant, so instead we have taken the 
approach of validating any signiﬁ  cant ﬁ  ndings in an indepen-
dent cohort. Replication of any genetic association ﬁ  nding 
is vital in establishing conﬁ  dence in a discovery but this can 
be challenging in the ﬁ  eld of pharmacogenetics for a number 
of reasons, ﬁ  rstly the issue of small sample sizes in many of 
these studies. Collecting large sample sizes for pharmacoge-
netic studies is much more difﬁ  cult compared to collecting dis-
ease case-control cohorts due to the more detailed clinical and 
phenotypic data required.    5    Secondly it is only recently that a 
standard measure of how a child responds to a particular treat-
ment in JIA has been developed    10    and so studies started before 
that time may have used slightly different response criteria and 
so results may be difﬁ  cult to compare. Finally different SNPs 
could be studied, again making comparison between studies 
difﬁ  cult. 
  In this study we have attempted to validate our initial ﬁ  nd-
ings in an independent cohort of patients with JIA collected in 
the US. Genome-wide association study data on a cohort of 
children who also have data on MTX response was available 
for analysis. Unfortunately the SNP in   ITPA   had not been geno-
typed on the SNP array and there were no proxy SNPs (r  2  >0.8). 
There was no evidence for association of any SNP within the 
  ITPA   gene in this cohort. Therefore this ﬁ  nding still requires 
validation in an independent dataset. One of the two SNPs in 
  ATIC  , which were associated with response to MTX in the UK 
CHARMS cohort, showed validated association in this inde-
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